<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment to target fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (FBG), postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> (<z:chebi fb="73" ids="53262">PPG</z:chebi>) and HbA(1c) are essential in the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> to reduce the risk of vascular complications </plain></SENT>
<SENT sid="1" pm="."><plain>Early combination therapy with oral agents is increasingly being seen as important to achieve this </plain></SENT>
<SENT sid="2" pm="."><plain>Repaglinide, a rapid-acting insulin secretagogue, targets <z:chebi fb="73" ids="53262">PPG</z:chebi>, and <z:chebi fb="0" ids="6801">metformin</z:chebi>, an insulin sensitizer, targets FBG </plain></SENT>
<SENT sid="3" pm="."><plain>Because of their complementary modes of action these therapies are frequently given as combination therapy in separate tablets </plain></SENT>
<SENT sid="4" pm="."><plain>To overcome the issues with adherence to multiple tablets, repaglinide and <z:chebi fb="0" ids="6801">metformin</z:chebi> are now available in a fixed-dose combination (<z:chebi fb="17" ids="38848">FDC</z:chebi>) </plain></SENT>
<SENT sid="5" pm="."><plain>Repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> is bioequivalent to each tablet given separately, suggesting that the efficacy and safety profile is similar </plain></SENT>
<SENT sid="6" pm="."><plain>There is no effect of food on repaglinide when in the <z:chebi fb="17" ids="38848">FDC</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> is as effective in reducing HbA(1c) and FBG whether given twice or three times daily, with a similar safety profile </plain></SENT>
<SENT sid="8" pm="."><plain>Repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> twice daily is as effective in reducing HbA(1c) and FBG as <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> with a similar safety profile, but unlike the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi>, repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> improves the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile </plain></SENT>
<SENT sid="9" pm="."><plain>Repaglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> represents a new option in the pursuit of achieving <z:chebi fb="105" ids="17234">glucose</z:chebi> targets and reducing vascular risk in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, with the advantage of improving adherence </plain></SENT>
</text></document>